Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Early notable gainers among liquid option names on May 20th » 09:55
05/20/22
05/20
09:55
05/20/22
09:55
MTCH

Match Group

$77.57 /

+2.53 (+3.37%)

, FTNT

Fortinet

$285.73 /

+10.72 (+3.90%)

, VFC

VF Corp.

$46.63 /

+2 (+4.48%)

, NOW

ServiceNow

$437.11 /

+10.06 (+2.36%)

, PFE

Pfizer

$51.85 /

+1.195 (+2.36%)

Notable gainers among…

Notable gainers among liquid option names this morning include Match Group (MTCH) $78.43 +3.38, Fortinet (FTNT) $287.08 +11.92, V F Corp (VFC) $46.37 +1.76, ServiceNow (NOW) $443.37 +16.61, and Pfizer (PFE) $52.59 +1.94.

ShowHide Related Items >><<
VFC VF Corp.
$46.63 /

+2 (+4.48%)

PFE Pfizer
$51.85 /

+1.195 (+2.36%)

NOW ServiceNow
$437.11 /

+10.06 (+2.36%)

MTCH Match Group
$77.57 /

+2.53 (+3.37%)

FTNT Fortinet
$285.73 /

+10.72 (+3.90%)

MTCH Match Group
$77.57 /

+2.53 (+3.37%)

05/10/22 Piper Sandler
Match Group suit against Google not surprising, says Piper Sandler
05/09/22 Wells Fargo
Wells Fargo upgrades Match Group to Overweight, lowers price target to $115
05/09/22 Wells Fargo
Match Group upgraded to Overweight from Equal Weight at Wells Fargo
05/05/22 RBC Capital
Match Group price target lowered to $115 from $150 at RBC Capital
FTNT Fortinet
$285.73 /

+10.72 (+3.90%)

05/12/22 BMO Capital
Fortinet price target lowered to $325 from $360 at BMO Capital
05/11/22 Daiwa
Fortinet upgraded to Buy from Outperform at Daiwa
05/11/22 Deutsche Bank
Fortinet price target lowered to $300 from $320 at Deutsche Bank
05/11/22 KeyBanc
Fortinet price target lowered to $353 from $410 at KeyBanc
VFC VF Corp.
$46.63 /

+2 (+4.48%)

05/20/22 Wedbush
VF Corp. price target lowered to $50 from $61 at Wedbush
05/20/22 Credit Suisse
VF Corp. price target lowered to $61 from $81 at Credit Suisse
05/20/22 Stifel
VF Corp. price target lowered to $42 from $74 at Stifel
05/20/22 Baird
VF Corp. price target lowered to $60 from $80 at Baird
NOW ServiceNow
$437.11 /

+10.06 (+2.36%)

05/18/22 Wells Fargo
ServiceNow initiated with an Overweight at Wells Fargo
05/10/22 Truist
ServiceNow price target lowered to $600 from $700 at Truist
04/28/22 BMO Capital
ServiceNow price target raised to $595 from $570 at BMO Capital
04/28/22 Morgan Stanley
ServiceNow price target lowered to $745 from $810 at Morgan Stanley
PFE Pfizer
$51.85 /

+1.195 (+2.36%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
VFC VF Corp.
$46.63 /

+2 (+4.48%)

PFE Pfizer
$51.85 /

+1.195 (+2.36%)

NOW ServiceNow
$437.11 /

+10.06 (+2.36%)

MTCH Match Group
$77.57 /

+2.53 (+3.37%)

FTNT Fortinet
$285.73 /

+10.72 (+3.90%)

PFE Pfizer
$51.85 /

+1.195 (+2.36%)

FTNT Fortinet
$285.73 /

+10.72 (+3.90%)

VFC VF Corp.
$46.63 /

+2 (+4.48%)

PFE Pfizer
$51.85 /

+1.195 (+2.36%)

NOW ServiceNow
$437.11 /

+10.06 (+2.36%)

MTCH Match Group
$77.57 /

+2.53 (+3.37%)

FTNT Fortinet
$285.73 /

+10.72 (+3.90%)

VFC VF Corp.
$46.63 /

+2 (+4.48%)

PFE Pfizer
$51.85 /

+1.195 (+2.36%)

NOW ServiceNow
$437.11 /

+10.06 (+2.36%)

MTCH Match Group
$77.57 /

+2.53 (+3.37%)

FTNT Fortinet
$285.73 /

+10.72 (+3.90%)

Thursday
Periodicals
CDC panel backs booster dose for Pfizer COVID vaccine for kids aged 5-11 » 15:56
05/19/22
05/19
15:56
05/19/22
15:56
PFE

Pfizer

$50.41 /

+ (+0.00%)

, BNTX

BioNTech

$165.98 /

+8.82 (+5.61%)

A CDC advisory panel has…

A CDC advisory panel has voted 11-1, with one abstention, to back a booster dose of the Pfizer (PFE) and BioNTech (BNTX) COVID vaccine for children aged five to eleven years old, according to multiple media reports.

ShowHide Related Items >><<
PFE Pfizer
$50.41 /

+ (+0.00%)

BNTX BioNTech
$165.98 /

+8.82 (+5.61%)

PFE Pfizer
$50.41 /

+ (+0.00%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
BNTX BioNTech
$165.98 /

+8.82 (+5.61%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
PFE Pfizer
$50.41 /

+ (+0.00%)

BNTX BioNTech
$165.98 /

+8.82 (+5.61%)

PFE Pfizer
$50.41 /

+ (+0.00%)

BNTX BioNTech
$165.98 /

+8.82 (+5.61%)

PFE Pfizer
$50.41 /

+ (+0.00%)

BNTX BioNTech
$165.98 /

+8.82 (+5.61%)

PFE Pfizer
$50.41 /

+ (+0.00%)

BNTX BioNTech
$165.98 /

+8.82 (+5.61%)

Recommendations
GlaxoSmithKline price target raised to 1,750 GBp at Deutsche Bank » 15:00
05/19/22
05/19
15:00
05/19/22
15:00
GSK

GlaxoSmithKline

$43.62 /

+0.354625 (+0.82%)

Deutsche Bank analyst…

Deutsche Bank analyst Emmanuel Papadakis raised the firm's price target on GlaxoSmithKline to 1,750 GBp from 1,600 GBp and keeps a Hold rating on the shares.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$43.62 /

+0.354625 (+0.82%)

GSK GlaxoSmithKline
$43.62 /

+0.354625 (+0.82%)

05/17/22 Roth Capital
Ideaya Biosciences price target raised to $46 from $42 at Roth Capital
05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
04/29/22 Barclays
GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays
04/28/22 JPMorgan
GlaxoSmithKline price target raised to 1,900 GBp from 1,740 GBp at JPMorgan
GSK GlaxoSmithKline
$43.62 /

+0.354625 (+0.82%)

GSK GlaxoSmithKline
$43.62 /

+0.354625 (+0.82%)

GSK GlaxoSmithKline
$43.62 /

+0.354625 (+0.82%)

GSK GlaxoSmithKline
$43.62 /

+0.354625 (+0.82%)

Conference/Events
Pfizer management to meet with Oppenheimer » 04:55
05/19/22
05/19
04:55
05/19/22
04:55
PFE

Pfizer

$50.41 /

-0.93 (-1.81%)

Meeting to be held in New…

Meeting to be held in New York on May 19 hosted by Oppenheimer.

ShowHide Related Items >><<
PFE Pfizer
$50.41 /

-0.93 (-1.81%)

PFE Pfizer
$50.41 /

-0.93 (-1.81%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
PFE Pfizer
$50.41 /

-0.93 (-1.81%)

PFE Pfizer
$50.41 /

-0.93 (-1.81%)

PFE Pfizer
$50.41 /

-0.93 (-1.81%)

PFE Pfizer
$50.41 /

-0.93 (-1.81%)

Tuesday
Hot Stocks
Pfizer, BioNTech receive FDA emergency use authorization for child booster » 11:44
05/17/22
05/17
11:44
05/17/22
11:44
PFE

Pfizer

$51.32 /

+0.64 (+1.26%)

, BNTX

BioNTech

$159.20 /

+7.99 (+5.28%)

Pfizer (PFE) and BioNTech…

Pfizer (PFE) and BioNTech (BNTX) announced the Food and Drug Administration expanded emergency use authorization to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children five through 11 years of age. The booster dose is given at least five months after the second dose of the two-dose primary series and is the same 10-microgram dose of the Pfizer-BioNTech COVID-19 Vaccine. The companies have already submitted an application to the European Medicines Agency for a booster dose in this age group and are planning to file with other regulatory agencies around the world.

ShowHide Related Items >><<
PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

PFE Pfizer
$51.32 /

+0.64 (+1.26%)

BNTX BioNTech
$159.20 /

+7.99 (+5.28%)

Hot Stocks
FDA expands eligibility for Pfizer-BioNTech booster to kids 5-11 years old » 10:16
05/17/22
05/17
10:16
05/17/22
10:16
PFE

Pfizer

$50.69 /

+0.01 (+0.02%)

, BNTX

BioNTech

$156.13 /

+4.92 (+3.25%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer (PFE) BioNTech (BNTX) COVID-19 Vaccine, authorizing the use of a single booster dose for administration to individuals 5 through 11 years of age at least five months after completion of a primary series with the Pfizer-BioNTech COVID-19 Vaccine. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research, said, "Since authorizing the vaccine for children down to 5 years of age in October 2021, emerging data suggest that vaccine effectiveness against COVID-19 wanes after the second dose of the vaccine in all authorized populations. The FDA has determined that the known and potential benefits of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series outweigh its known and potential risks and that a booster dose can help provide continued protection against COVID-19 in this and older age groups." Reference Link

ShowHide Related Items >><<
PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

PFE Pfizer
$50.69 /

+0.01 (+0.02%)

BNTX BioNTech
$156.13 /

+4.92 (+3.25%)

Recommendations
Ideaya Biosciences price target raised to $46 from $42 at Roth Capital » 09:47
05/17/22
05/17
09:47
05/17/22
09:47
IDYA

Ideaya Biosciences

$10.41 /

-0.005 (-0.05%)

, GSK

GlaxoSmithKline

$44.52 /

+0.195 (+0.44%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Ideaya Biosciences (IDYA) to $46 from $42 and keeps a Buy rating on the shares post the Q1 results. The Phase 1/2 options data package for IDE397 is on track for mid-year, which support its addition to the model, Jallah tells investors in a research note. The analyst points out that Ideaya could become eligible for a $50M opt-in payment from GlaxoSmithKline (GSK).

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$10.41 /

-0.005 (-0.05%)

GSK GlaxoSmithKline
$44.52 /

+0.195 (+0.44%)

IDYA Ideaya Biosciences
$10.41 /

-0.005 (-0.05%)

03/15/22 Stifel
Ideaya Biosciences price target lowered to $17 from $20 at Stifel
03/15/22 Roth Capital
Ideaya Biosciences' IDE397 update 'incrementally positive,' says Roth Capital
03/10/22 Stifel
Ideaya Biosciences upgraded to Buy from Hold at Stifel
01/06/22 Northland
Ideaya Biosciences named a top pick for 2022 at Northland
GSK GlaxoSmithKline
$44.52 /

+0.195 (+0.44%)

05/13/22 Jefferies
Roche downgraded to Hold from Buy at Jefferies
04/29/22 Barclays
GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays
04/28/22 JPMorgan
GlaxoSmithKline price target raised to 1,900 GBp from 1,740 GBp at JPMorgan
04/14/22 Barclays
GlaxoSmithKline price target raised to 1,775 GBp from 1,675 GBp at Barclays
IDYA Ideaya Biosciences
$10.41 /

-0.005 (-0.05%)

GSK GlaxoSmithKline
$44.52 /

+0.195 (+0.44%)

  • 08
    Jul
GSK GlaxoSmithKline
$44.52 /

+0.195 (+0.44%)

GSK GlaxoSmithKline
$44.52 /

+0.195 (+0.44%)

GSK GlaxoSmithKline
$44.52 /

+0.195 (+0.44%)

Monday
Conference/Events
Pfizer management to meet with Oppenheimer » 16:55
05/16/22
05/16
16:55
05/16/22
16:55
PFE

Pfizer

$50.68 /

+0.78 (+1.56%)

Meeting to be held in New…

Meeting to be held in New York on May 19 hosted by Oppenheimer.

ShowHide Related Items >><<
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

Hot Stocks
Mirati Therapeutics appoints Laurie Stelzer as CFO » 16:33
05/16/22
05/16
16:33
05/16/22
16:33
MRTX

Mirati Therapeutics

$56.42 /

-0.36 (-0.63%)

, PFE

Pfizer

$50.68 /

+0.78 (+1.56%)

, TAK

Takeda Pharmaceutical

$14.27 /

-0.085 (-0.59%)

Mirati Therapeutics…

Mirati Therapeutics (MRTX) the appointment of Laurie Stelzer as the Company's CFO effective May 16. Laurie will report to the Company's CEO, David Meek. Laurie joins the Company most recently from Arena Pharmaceuticals, acquired by Pfizer (PFE), where she served as Executive Vice President and CFO since 2020. She brings 25 years of biopharma industry experience to her role in leading the company's finance functions. Prior to joining Arena, Laurie was the CFO at Halozyme Therapeutics where she led the finance, information technology, business development, project management and site operations organizations. Prior to joining Halozyme, Laurie held senior management roles at Shire, acquired by Takeda (TAK), including Senior Vice President of Finance, Division CFO for the Regenerative Medicine Division, and Head of Investor Relations. Previously she held positions of increasing responsibility during her fifteen-year career at Amgen, spanning the areas of finance, treasury, global accounting, and international/emerging markets.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

05/05/22 Stifel
ASCO sets up as 'downside-biased' for Mirati investors, says Stifel
05/05/22 Citi
Mirati Therapeutics price target lowered to $208 from $227 at Citi
03/02/22 Citi
Mirati Therapeutics price target lowered to $227 from $244 at Citi
03/01/22 BMO Capital
Mirati Therapeutics price target lowered to $130 from $187 at BMO Capital
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
03/31/22 Canaccord
Canaccord starts Morphic at Buy, sees potential to take share from Takeda
02/11/22 BTIG
Protagonist Therapeutics initiated with a Buy at BTIG
02/11/22 BTIG
Morphic initiated with a Buy at BTIG
PFE Pfizer
$50.68 /

+0.78 (+1.56%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

  • 11
    Nov
TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

TAK Takeda Pharmaceutical
$14.27 /

-0.085 (-0.59%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

MRTX Mirati Therapeutics
$56.42 /

-0.36 (-0.63%)

PFE Pfizer
$50.68 /

+0.78 (+1.56%)

Periodicals
Pfizer, BioNTech Covid booster for kids 5-11 expected to be authorized, NYT says » 15:59
05/16/22
05/16
15:59
05/16/22
15:59
PFE

Pfizer

$50.67 /

+0.77 (+1.54%)

, BNTX

BioNTech

$151.47 /

-7.33 (-4.62%)

The Pfizer (PFE)-BioNTech…

The Pfizer (PFE)-BioNTech (BNTX) Covid-19 vaccine booster shot is expected to be authorized by the FDA for children ages 5 to 11, The New York Times' Sharon LaFraniere reports, citing multiple people familiar with the plan. Last month, the companies said that the booster significantly increased the level of neutralizing antibodies against both the original version of the virus and the omicron variant in a small clinical trial of 140 children. A meeting of outside vaccine experts on an advisory committee to the Centers for Disease Control and Prevention has been scheduled for Thursday, according to the report. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$50.67 /

+0.77 (+1.54%)

BNTX BioNTech
$151.47 /

-7.33 (-4.62%)

PFE Pfizer
$50.67 /

+0.77 (+1.54%)

05/11/22 H.C. Wainwright
Biohaven Pharmaceutical downgraded to Neutral from Buy at H.C. Wainwright
05/11/22 Wedbush
Global Blood Therapeutics added to Best Ideas List at Wedbush
05/05/22 Stifel
Stifel keeps Buy rating on Arvinas, lowers price target to $82
05/04/22 Wells Fargo
Pfizer price target lowered to $55 from $60 at Wells Fargo
BNTX BioNTech
$151.47 /

-7.33 (-4.62%)

04/12/22 H.C. Wainwright
BioNTech price target lowered to $298 from $339 at H.C. Wainwright
04/11/22 H.C. Wainwright
H.C. Wainwright bullish on Matinas as LNC platform attracts BioNTech collab
04/05/22 Canaccord
BioNTech price target lowered to $300 from $450 at Canaccord
02/23/22 H.C. Wainwright
BioNTech price target lowered to $336 from $366 at H.C. Wainwright
PFE Pfizer
$50.67 /

+0.77 (+1.54%)

BNTX BioNTech
$151.47 /

-7.33 (-4.62%)

PFE Pfizer
$50.67 /

+0.77 (+1.54%)

BNTX BioNTech
$151.47 /

-7.33 (-4.62%)

PFE Pfizer
$50.67 /

+0.77 (+1.54%)

BNTX BioNTech
$151.47 /

-7.33 (-4.62%)

PFE Pfizer
$50.67 /

+0.77 (+1.54%)

BNTX BioNTech
$151.47 /

-7.33 (-4.62%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.